The Combination of circEPSTII and MIF Offers Diagnostic Value for Endometrial Cancer

Background: Circular RNAs (circRNAs) exhibit unique patterns of expression and high levels of stability in patient plasma samples such that they represent ideal non-invasive biomarkers that can be leveraged to detect a wide array of diseases including endometrial cancer (EC). This study was designed...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of general medicine Vol. 17; p. 1395
Main Authors Cui, Zhili, Zhou, Liyuan, An, Xin, Liu, Wenli, Li, Jingxia, Zhang, Yueping, Zhang, Wei
Format Journal Article
LanguageEnglish
Published Dove Medical Press Limited 30.04.2024
Subjects
Cancer
Development and progression
Diagnosis
Endometrial cancer
Oncology, Experimental
China
Taiwan
Online AccessGet full text

Cover

More Information
Summary:Background: Circular RNAs (circRNAs) exhibit unique patterns of expression and high levels of stability in patient plasma samples such that they represent ideal non-invasive biomarkers that can be leveraged to detect a wide array of diseases including endometrial cancer (EC). This study was designed to identify circRNAs with potential diagnostic utility in serum samples from EC patients while also evaluating the utility of macrophage migration inhibitory factor (MIF) as a biomarker when screening for this form of cancer in the clinic. Methods: Levels of circEPSTI1 and MIF were assessed in the plasma of EC patients and healthy subjects (n=186 each) through qPCR and ELISAs. The diagnostic utility of these biomarkers was assessed with receiver operating characteristic curve (ROC) analyses. Results: Relative to healthy subjects, EC patient serum contained significantly elevated circEPSTI1 and MIF. An association was noted between circEPSTI1 expression in stages, histologic grade, and residual tumor. ROC curves confirmed that serum circEPSTI1 levels distinguished between controls and patients with EC with an Area of 0.835 and serum MIF levels distinguished between controls and patients with EC with an Area of 0.6646. When instead diagnosing patients based on the combination of MIF and circEPSTI1, the Area further rose to 0.8604. Conclusion: Assessing the combination of circEPSTI1 and MIF may be a viable approach to reliably diagnosing EC. Keywords: circEPSTI1, MIF, diagnostic biomarker, endometrial cancer
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S441861